Skip to main content

Table 2 Monthly seizure frequency (MSF) and proportion of seizure free animals during phase 1 and 2

From: Efficacy, safety, and tolerability of imepitoin in dogs with newly diagnosed epilepsy in a randomized controlled clinical study with long-term follow up

 

High-dose N = 64

Low-Dose N = 60 (59a)

Significanceb, high-dose vs. low-dose group

ᅟMSF Baseline Mean ± SD

2.9 ± 2.7

2.0 ± 1.7

p = 0.030

ᅟ95 CI of mean

2.2 - 3.6

1.6 – 2.5

ᅟMSF During phase 1 Mean ± SD

1.2 ± 1.7

1.3 ± 1.8

p = 0.751

ᅟ95 CI of mean

0.7 - 1.6

0.8 - 1.7

ᅟMSF Change to baseline Mean ± SD

−1.7 ± 2.8

−0.8 ± 2.0

p = 0.044

ᅟ95 CI of mean

−2.4 - -1.1

−1.3 - -0.3

ᅟSeizure free animals during phase 1 [n]

24 of 64

19 of 60

p = 0.495

Transition to phase 2

N = 53 of 64

N = 47 of 60

 

ᅟMSF During phase 2 Mean ± SD

1.2 ± 1.3

0.9 ± 1.4

p = 0.269

ᅟ95 CI of mean

0.8 - 1.5 p = 0.688c

0.5 - 1.4 p =0.369c

ᅟSeizure free animals at start of phase 2 [n]

16 of 53

14 of 47

p = 0.965

ᅟSeizure free animals during phase 2 [n]

17 of 53 p = 0.540c

22 of 47 p = 0.110c

p = 0.132

  1. aFor one animal no baseline data were available. It could therefore not be included in the primary efficacy evaluation
  2. bThe p-value for the difference in mean MSF and change in MSF was based on the two-sided two-sample t-test; the p-value difference in the proportion of seizure free animals was based on the two-sided chi-square test for two samples
  3. cComparison of results from phase 1 and phase 2 of the study